PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.
about
Genomic profiling in luminal breast cancerSignatures of breast cancer metastasis at a glanceHormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal WomenComparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.Network Analysis Reveals A Signaling Regulatory Loop in the PIK3CA-mutated Breast Cancer Predicting Survival Outcome.Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomesA Comprehensive Analysis of CXCL12 Isoforms in Breast Cancer(1,2.)Age-specific changes in intrinsic breast cancer subtypes: a focus on older womenGenetic background may contribute to PAM50 gene expression breast cancer subtype assignmentsBreast Cancer Update 2014 - Focus on the Patient and the Tumour.Defining breast cancer intrinsic subtypes by quantitative receptor expression.Development and verification of the PAM50-based Prosigna breast cancer gene signature assayCrossLink: a novel method for cross-condition classification of cancer subtypesResponse and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-studyBiological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility.The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis.Circular RNAs and their associations with breast cancer subtypes.Taxane benefit in breast cancer--a role for grade and chromosomal stability.A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse.Prognostic immune-related gene models for breast cancer: a pooled analysis.Developing a new generation of breast cancer clinical gene expression testsAssessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer.Practical consensus recommendations regarding the management of hormone receptor positive early breast cancer in elderly women.
P2860
Q26862681-829B8269-CE59-497D-84AE-17CB9891AB1BQ28071451-85D75450-AD22-4037-A50B-353E11E392D1Q28077637-3225EC62-A949-44DB-82F3-E9F8E464689DQ30315367-F05577B4-A5DE-424B-B0AF-346DA6FFF1A2Q33631628-2413F57A-EFDC-42D5-8329-C6C2BCD71CDDQ33827057-0502DC54-7C98-46C1-8BD4-F3D93F4D5232Q33883406-7DB560BF-F27D-4F4C-8658-2E103F8CA06AQ33927000-7CAAB06D-5961-4843-AC26-B905510F8AF1Q34092009-5420771C-4CFA-40EE-8634-A92B72EE3484Q34359310-A9654790-AB5D-4D66-AD18-33923E91289AQ34981442-CCAD4CE6-57C2-4B9E-B8FA-D37C9F7A8CE5Q35180940-AF8E6870-E0E7-49FF-A7A6-95A0BCCDA761Q35586697-D1265630-2366-4E71-B5A4-F9C6848E074FQ35752868-9434BD4E-7E42-4F0B-9D4F-637428E961C0Q36111302-F053AE20-7CCB-447B-95FE-E698C744FA92Q36383626-1E536CD7-CBDF-4AD7-BA6A-C3F8CDD7BE54Q36678505-F8D2C905-020B-45DE-B898-0F903F31C25DQ36994974-46D18FE7-E2E4-4D5A-87D5-4DD05FFD9644Q37383276-D8F4CDCB-C07C-473C-BC12-767FA36C869BQ37510518-E68E7386-3080-471E-8F2A-3FED24581422Q37697101-44DEC003-EC39-4B3B-A2AB-F12B3816F5B2Q38104568-A625F2FA-C799-493A-9BA1-5280A8DCBCE8Q39141610-DBC6DD01-5E37-4089-903E-64A86AAC312EQ42001306-4E7470B1-5505-4B54-A457-21F54307675CQ42737349-58DDA844-6FA8-40F9-8C0C-B33BD7AA166DQ47138534-5397E81A-0206-4A3E-BA59-A2A1B678A5EBQ55208842-180D053C-298D-46DF-A669-F20F8F4505B8
P2860
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.
@ast
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.
@en
type
label
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.
@ast
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.
@en
prefLabel
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.
@ast
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.
@en
P2093
P2860
P50
P1476
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.
@en
P2093
Alvaro Rodríguez-Lescure
Amparo Ruiz
Ana M García
Blanca Munárriz
Brandelyn N Pitcher
Carmen Crespo
Carole Davis
Clifford Hudis
César A Rodríguez
David P Tuck
P2860
P2888
P304
P356
10.1007/S10549-013-2416-2
P407
P577
2013-02-20T00:00:00Z